EUVIMEDEUVIMED entdecken
ValidierungsstudieMultizentrische StudieOpen Access

Prospective Validation of the Movement Disorder Society Prodromal Multiple System Atrophy Criteria in Pure Autonomic Failure

Patricio Millar Vernetti iD, Jose-Alberto Palma iD, Italo Biaggioni iD, Cyndya A Shibao iD, Roy Freeman iD, Christopher Gibbons iD, Wolfgang Singer iD, Elizabeth A Coon iD, Mitchell G Miglis iD, Florian Krismer iD, Alessandra Fanciulli iD, David S Goldstein iD und 2 weitere

Movement Disorders · 2026

DOI: 10.1002/mds.70417 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift Movement Disorders, 2026. Verfasst von Patricio Millar Vernetti und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, New York University Grossman School of Medicine, New York, NY, USA. Hauptthemen laut MEDLINE: Multiple System Atrophy, Pure Autonomic Failure. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NINDS NIH HHS, The Algard Family MSA Innovation Fund, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The Movement Disorder Society (MDS) research criteria for possible prodromal multiple system atrophy (PP‐MSA) have not been prospectively validated.

Objective

To evaluate the diagnostic performance of the PP‐MSA criteria in a longitudinal cohort of patients with pure autonomic failure (PAF) and to assess whether additional clinical features improve their predictive value.

Methods

Seventy‐six patients with PAF enrolled across eight centers in the Natural History Study of the Synucleinopathies were followed for ≥6 years or until phenoconversion. Participants were classified according to MDS PP‐MSA criteria and followed for development of MSA, Parkinson's disease, or dementia with Lewy bodies. Diagnostic performance was assessed longitudinally. Analyses were repeated using a stricter olfactory threshold (University of Pennsylvania Smell Identification Test [UPSIT]≤28) as an exclusion criterion.

Results

Thirty‐eight participants met PP‐MSA criteria, of whom 12 phenoconverted to MSA within 6 years. Sensitivity was 100% at year 1 and 92% at year 6, whereas specificity ranged from 56% to 67%. Positive predictive value (PPV) ranged from 21% to 34%. Applying a stricter olfactory threshold improved specificity (90%–97%) and PPV (53%–83%), with a modest reduction in sensitivity (to 83%). Participants who phenoconverted to MSA were younger, had more severe urinary dysfunction, and greater orthostatic heart rate responses.

Conclusions

The PP‐MSA criteria demonstrate high sensitivity but limited specificity in patients with PAF. A stricter olfactory threshold improves diagnostic performance and may enhance cohort enrichment for clinical trials. © 2026 International Parkinson and Movement Disorder Society. This article has been contributed to by U.S. Government employees and their work is in the public domain in the USA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple System AtrophyPure Autonomic FailureHumansFemaleMaleAgedMiddle AgedProdromal SymptomsProspective StudiesLongitudinal StudiesSensitivity and SpecificityPredictive Value of TestsParkinson Disease

Stichwörter der Autor:innen

Multiple system atrophyPure autonomic failure (PAF)Synucleinopathiesheart rate responsehyposmiaorthostatic hypotensionprodromal criteriaurinary retention

Autor:innen und Institutionen

  • Department of Neurology, New York University Grossman School of Medicine, New York, NY, USA.
  • Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
  • Department of Neurology, Brigham and Women's Hospital, Harvard University, Boston, MA, USA.
  • Department of Neurology, Mayo Clinic Rochester, Rochester, MN, USA.
  • Department of Neurology, Stanford University, Stanford, CA, USA.
  • Department of Neurology, Medical University Innsbruck, Innsbruck, Austria.

ORCID-Profile: Patricio Millar Vernetti, Jose-Alberto Palma, Italo Biaggioni, Cyndya A Shibao, Roy Freeman, Christopher Gibbons, Wolfgang Singer, Elizabeth A Coon, Mitchell G Miglis, Florian Krismer, Alessandra Fanciulli, David S Goldstein, Rebecca A Betensky, Horacio Kaufmann

Förderung

  • NINDS NIH HHS
  • The Algard Family MSA Innovation Fund
  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Millar Vernetti, P., Palma, J. A., Biaggioni, I., Shibao, C. A., Freeman, R., Gibbons, C., Singer, W., Coon, E. A., Miglis, M. G., Krismer, F., Fanciulli, A., Goldstein, D. S., Betensky, R. A., & Kaufmann, H. (2026). Prospective Validation of the Movement Disorder Society Prodromal Multiple System Atrophy Criteria in Pure Autonomic Failure. Movement Disorders. https://doi.org/10.1002/mds.70417

Vancouver

Millar Vernetti P, Palma JA, Biaggioni I, Shibao CA, Freeman R, Gibbons C, et al. Prospective Validation of the Movement Disorder Society Prodromal Multiple System Atrophy Criteria in Pure Autonomic Failure. Movement Disorders. 2026. doi:10.1002/mds.70417

BibTeX
@article{MillarVernetti2026,
  author = {Millar Vernetti, Patricio and Palma, Jose-Alberto and Biaggioni, Italo and Shibao, Cyndya A and Freeman, Roy and Gibbons, Christopher and Singer, Wolfgang and Coon, Elizabeth A and Miglis, Mitchell G and Krismer, Florian and Fanciulli, Alessandra and Goldstein, David S and Betensky, Rebecca A and Kaufmann, Horacio},
  title = {Prospective Validation of the Movement Disorder Society Prodromal Multiple System Atrophy Criteria in Pure Autonomic Failure},
  journal = {Movement Disorders},
  year = {2026},
  doi = {10.1002/mds.70417}
}
Kostenlos starten →